Barbara Domayne-Hayman

Dr Barbara Domayne-Hayman was Entrepreneur-in-Residence at SBC from Dec 2012 – Jan 2015, mentoring manyof the tenant companies and working with the SBC management team on a varietyof initiatives. These included SBC’s first Open Innovation Challenge inNeurodegenerative Disease, in which she continues to be involved, as well otherstrategic projects. Barbara remains a regular visitor to SBC and would be happyto provide advice on:

  • Developing and fine-tuning business strategy, identification of key milestones, value inflection points and exit route for investors
  • Consideration of key commercial aspects, including market attractiveness, competitive positioning, pricing and re-imbursement (never too early to start!)
  • Fund-raising, whether from venture capital or angel investors
  • Non-dilutive funding, particularly from Innovate UK and from US government sources
  • Business development / partnering strategy and contacts
  • Act as sounding board on other issues facing early stage companies in business-building, including team composition.


Barbara has a broad range of commercial, fund-raising and general management experience, with many years of business development. She is currently Chief Business Officer at Autifony Therapeutics and Chairman of Puridify. She was until recently ‘Entrepreneur-in-residence’ at the Stevenage Bioscience Catalyst. Previously, Barbara was CEO of Stabilitech, a platform technology company stabilising vaccines and other biologics, for over four years. She raised funding, including considerable amounts from non-dilutive sources such as the US Department of Defense as well as Innovate UK (previously Technology Strategy Board), established multiple commercial collaborations and built the team from early stage. Prior to this, she was Commercial Director at Arrow Therapeutics, an antiviral drug discovery and development company, for over four years, until the company was acquired by AstraZeneca in 2007. Before working at Arrow, Barbara was Senior Business Development Manager at Celltech. She previously held senior international commercial positions at Zeneca where she worked for over ten years. She has also consulted in Life Sciences for Ernst & Young Strategy Group, and holds a Sloan Fellowship from London Business School. She has a BA and D.Phil in chemistry, from the University of Oxford.

Funding Partners: